This trial is evaluating whether Fluorine F 18 L-glutamate Derivative BAY94-9392 will improve 1 primary outcome and 1 secondary outcome in patients with Multiple Pulmonary Nodules. Measurement will happen over the course of Up to 5 years.
This trial requires 50 total participants across 2 different treatment groups
This trial involves 2 different treatments. Fluorine F 18 L-glutamate Derivative BAY94-9392 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
The majority of the patients (94%) were managed with a total of 1060 procedures. The nodules' regression rate was 97% (nodules of 1-3 nodules responded equally good to total nodules' regression, while nodules of > 3 responded poorly.
Although no universally accepted treatment guidelines exist for the treatment of pulmonary nodules, specific considerations should be made according to the size, shape, extent, and patient health-care setting.
In the absence of any lung disease or history of prior pulmonary disease, multiple pulmonary nodules are a common incidental finding on low-dose CT scan used to screen patients for pulmonary embolism. The majority of nodules are<4 cm. There is significant overlap in prevalence of multiple nodules among patients with and without pulmonary embolism, suggesting that a noninvasive diagnostic test for pulmonary embolism is not yet available.
The number of patients with multiple pulmonary nodules a year in the United States is not known with reasonable accuracy. More than 30 have been misclassified as benign fibrous pseudotumours on computed tomography because of mistaken interpretation of CT findings in the setting of multiple pulmonary nodules. This confusion is due to the similarity in appearance, and hence interpretation, of lung metastases, pleural plaques and pulmonary lipodystrophy on CT with pulmonary fibroblastic hamartoma on surgical specimens. The true incidence of multiple pulmonary nodules and the prevalence of multiple lung neoplasms should be established with careful selection of pulmonary nodules requiring surgical excision and histologic interpretation.
There are many possible causes of multiple pulmonary nodules, including exposure to asbestos, drug toxicity, sarcoidosis, and tuberculosis. Diagnoses of multiple pulmonary nodules should be made cautiously, and a multidisciplinary approach is important.
Most patients with multiple pulmonary nodules have benign pathology detected on HRCT. The presence of halo signs on chest radiographs of patients with multiple pulmonary nodules is highly suggestive of the presence of infectious causes. HRCT-visible halo signs have a high positive predictive value (88%) and can serve as an objective marker of a particular disease process, such as a fungal infection.
As F 18 L- glutamate is selectively accumulated in malignant tumours and its metabolism is influenced by different tumour characteristics, this justifies its use in PET/CT/MRI. The most frequently used combination is (S) -Bay94-9392 (CAS: [932-17-0, 5-fluoro-4-(phenylmethyl)phenyl]-2-\n(4′-fluoro)oxanorleucine (S) -octreotide, which is also the most frequently used combination when combined with (S)-methionine, and more rarely with (R) -metofoline or other peptides.
There is a trend for the F18-labelled radioligand to reveal a higher SUVmax-peak ratio over time in patients with metastatic and/or recurrent tumor than in those with metastatic- or nonresidual-type nonenhancing metastatic pulmonary nodules. This trend coincides with clinical responses. Further validation is necessary.
The (18)F-L-Glu derivative of DOTA-TATE exhibited excellent efficacy and promising safety profiles in two patients with metastatic nonseminomatous testicular carcinoma, with no side effects or toxicity.
With adequate follow-up and the use of adequate treatment, a small number of patients diagnosed with a multiple pulmonary nodule may remain asymptomatic. There is still an urgent need for early diagnostic tools and clinical trials to identify treatment options for patients with multiple pulmonary nodules.
With the help of this article, we were able to find the latest research for multiple pulmonary nodules. From this, clinicians may be able to have a better-informed decision for treatment for multiple pulmonary nodules if informed by the latest research.
We conclude that [LAM was the cause of both cases of IPN and MNP. The primary cause of MNP could be IPN itself or another process, not LAM in the majority of cases]] (https://medscape.com/article/what-is-the-primary-cause-of-multiple-pulmonary-nodules).